Patients with AMD often have low levels of CD59, a protein that protects the retina from damage caused by an essential part of the body’s natural immune response called complement. JNJ - Free Report) pharmaceutical unit, Janssen Pharmaceuticals, Inc., announced that it has acquired rights to privately-owned biotechnology company Hemera Biosciences, LLC’s investigational gene.
#Hemera biosciences archive
Community submitted dataĪssociated sectors: Life Sciences Biologics Healthtech SARS-CoV-2 Vaccine Cancer Melanoma Immunotherapy Diagnostics DNA RNA Peptide Therapies Vaccines Biotech Website archive shows the site was first archived on 2016. Financial terms of the transaction with Hemera Biosciences, a privately-owned biotechnology company, are not being disclosed. He and his wife, Stephanie 92C, reside in Needham, Massachusetts. 2, 2020 /PRNewswire/ - Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, today announced the acquisition of rights to Hemera Biosciences, LLC's investigational gene therapy HMR59, administered as a one-time, outpatient, intravitreal injection to help preserve vision in patients with geographic atrophy, a late-stage and severe. Rogers graduated from Emory College in 1992 and Emory School of Medicine in 1996. He also serves as a trustee of the Paul and Phyllis Fireman Charitable Foundation and board member of One Family. We work directly with corporations and also with service providers (such as open innovation agencies, outsourced R&D consultants, and traditional crowd-sourcing companies) to provide them with our intelligent company discovery capabilities. Needham, Massachusetts Adam Rogers 92C 96M is the CEO and founder of Hemera Biosciences.
By structuring and analysing this information we are able to accurately match our clients needs with the start-ups, SMEs and other innovators that have the skills our clients need. We discover innovative companies from across the globe using our Company Discovery Engine, which trawls the web to harvest and aggregate company information at a scale, speed and efficiency that hasn’t previously been possible. Hemera Biosciences is pleased to announce that the FDA has granted safe to proceed status to the Investigational New Drug (IND) application for HMR59 on December 30, 2016. VentureRadar helps organisations innovate and generate new growth by connecting them to the emerging technologies and expertise that can solve their challenges.
0 kommentar(er)
